Xenon Pharmaceuticals Analyst Ratings
BenzingaApr 12 19:02
Xenon Pharmaceuticals Analyst Ratings
BenzingaApr 10 21:46
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
TipRanksMar 5 14:35
Xenon Pharmaceuticals Analyst Ratings
BenzingaMar 1 21:10
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk
MT NewswiresMar 1 21:09
Buy Rating Justified by Xenon Pharmaceuticals' Advanced Epilepsy Program and Growth Prospects in Neuroscience
TipRanksMar 1 15:45
Maintaining Buy Rating on Xenon Pharmaceuticals With a $60 Target Amidst XEN1101 Clinical Advancements
TipRanksJan 9 07:45
Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62
BenzingaJan 4 17:47
Xenon Pharmaceuticals Analyst Ratings
BenzingaJan 4 17:46
B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56
BenzingaJan 2 23:48
Xenon Pharmaceuticals Analyst Ratings
BenzingaJan 2 23:46
Stifel Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $62
BenzingaDec 18, 2023 23:57
Xenon Pharmaceuticals Analyst Ratings
BenzingaDec 18, 2023 23:56
Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63
BenzingaDec 8, 2023 18:29
Xenon Pharmaceuticals Analyst Ratings
BenzingaDec 8, 2023 18:27
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56
BenzingaNov 28, 2023 17:31
Xenon Pharmaceuticals Analyst Ratings
BenzingaNov 28, 2023 17:29
Maintained Buy Rating on Xenon Pharmaceuticals: Promising Signals for XEN1101 Despite Trial Challenges
TipRanksNov 28, 2023 07:15
Xenon Pharmaceuticals Analyst Ratings
BenzingaNov 9, 2023 23:44
Xenon Pharmaceuticals Analyst Ratings
BenzingaOct 25, 2023 01:35
No Data
No Data